Results 221 to 230 of about 10,879 (246)
Some of the next articles are maybe not open access.
Edaravone enhances the viability of ischemia/reperfusion flaps
Journal of Huazhong University of Science and Technology [Medical Sciences], 2017The purpose of the experiment was to study the efficacy of edaravone in enhancing flap viability after ischemia/reperfusion (IR) and its mechanism. Forty-eight adult male SD rats were randomly divided into 3 groups: control group (n=16), IR group (n=16), and edaravone-treated IR group (n=16). An island flap at left lower abdomen (6.0 cm×3.0 cm in size),
Shensong Kang +3 more
openaire +3 more sources
Edaravone Oral Suspension: A Neuroprotective Agent to Treat Amyotrophic Lateral Sclerosis.
American Journal of TherapeuticsBACKGROUND Amyotrophic lateral sclerosis (ALS) is characterized by loss of motor neurons due to degeneration of nerve cells within the brain and spinal cord. Early symptoms include limb weakness, twitching or muscle cramping, and slurred speech.
Priya Singh +4 more
semanticscholar +1 more source
[Edaravone: A New Treatment for ALS].
Brain and nerve = Shinkei kenkyu no shinpo, 2019In 1993, a mutation in the superoxyde dismutase gene, SOD1, was found causative for familial ALS, suggesting that free radical-related injury may be involved in ALS pathogenesis. Therefore, clinical trials were conducted with ALS patients using a free radical scavenger, edaravone, which was already approved for acute phase treatment of cerebral ...
Koji Abe, Toru Yamashita
openaire +3 more sources
Edaravone Oral Suspension (Radicava)
Canadian Journal of Health Technologies, 2023CADTH recommends that Radicava should be reimbursed by public drug plans for the treatment of patients with amyotrophic lateral sclerosis (ALS), if certain conditions are met. Radicava oral suspension should only be covered to treat patients with ALS provided that it is covered for a similar patient population and in a similar way to the ...
openaire +1 more source
Edaravone Therapy: From Bench to Bedside
2014Stroke, the second leading cause of death throughout the world, typically results in a drastic reduction in the quality of life. The free radical scavenger edaravone was developed from translational research mainly using animal stroke models. It was approved in Japan in April, 2001 as a neuroprotective drug for the treatment of acute cerebral ...
Toru Yamashita, Koji Abe
openaire +2 more sources
Edaravone suppresses degradation of type II collagen
Biochemical and Biophysical Research Communications, 2016Osteoarthritis (OA) is a degenerative joint disease affecting millions of people. The degradation and loss of type II collagen induced by proinflammatory cytokines secreted by chondrocytes, such as factor-α (TNF-α) is an important pathological mechanism to the progression of OA.
Guofeng Zhang +4 more
openaire +3 more sources
Protective effect of edaravone against endolymphatic hydrops
Acta Oto-Laryngologica, 2007Our findings suggest that edaravone prevented the production of reactive oxygen species (ROS). Edaravone also delayed the formation of endolymphatic hydrops in guinea pigs, but had no effect on endolymphatic hydrops.To analyse the protective effect of a free radical scavenger, edaravone, on endolymphatic hydrops.Guinea pigs were subjected to surgical ...
Masaya Takumida +5 more
openaire +3 more sources
Effects of edaravone, a radical scavenger, on hepatocyte transplantation
Journal of Hepato-Biliary-Pancreatic Sciences, 2014Hepatocyte transplantation (HTx) has yielded significant improvements in liver function and survival in experimentally induced acute liver failure and liver-based metabolic disease. However, transplantation is inefficient, and it is thought that transplanted hepatocytes have a shortened lifespan because of inflammation involving excess nitric oxide (NO)
Akihiko Horiguchi +7 more
openaire +3 more sources
Riluzole and edaravone: A tale of two amyotrophic lateral sclerosis drugs
Medicinal research reviews (Print), 2018Over the past decades, a multitude of experimental drugs have been shown to delay disease progression in preclinical animal models of amyotrophic lateral sclerosis (ALS) but failed to show efficacy in human clinical trials or are still waiting for ...
M. Jaiswal
semanticscholar +1 more source
Clinical usefulness of edaravone for acute liver injury
Journal of Gastroenterology and Hepatology, 2003AbstractBackground: Edaravone, a newly synthesized radical scavenger, has shown an excellent effect on treating stroke patients. The effect of edaravone on carbon tetrachloride (CCl4)‐induced acute liver injury was examined.Methods: Six rats were injected with CCl4 alone and six rats were intravenously injected with edaravone immediately after and 3 h ...
Satoshi Tsunematsu +6 more
openaire +3 more sources